Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study
Hematological Oncology - United Kingdom
doi 10.1002/hon.128_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley